SCHEMBL6624353

SCHEMBL6624353

Cc1ccn(-c2ccc(C(=O)Cl)cc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.53
OXTR P30559 3/20 0.48
AVPR1A P37288 3/20 0.48
AVPR2 P30518 3/20 0.48
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
HDAC4 P56524 1/20 0.47
MGLL Q99685 1/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
UBE2N P61088 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12436877 0.84 HTT (0.54) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL1770474 0.84 HTT (0.54) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL3657454 0.83 HTT (0.53) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL15935403 0.80 ALDH1A1 (0.55) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL6611595 0.76 AVPR2 (0.55) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL2615994 0.76 HTT (0.56) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL597553 0.76 HTT (0.56) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL1039420 0.76 NPC1 (0.57) HTTRAB9ANPC1MGLLMAPT
SCHEMBL12422701 0.75 HTT (0.59) HTTOXTRAVPR1AAVPR2RAB9A
SCHEMBL31227412 0.75 MAOA (0.44) HTTRAB9ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1183134-C Tricyclic vasopressin agonists 2005-01-05 CN disclosed
US-6831079-B1 Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone AMERICAN CYANAMID COMPANY 2004-12-14 US disclosed
EP-1000062-B1 TRICYCLIC VASOPRESSIN AGONISTS WYETH CORP (US) 2004-09-22 EP disclosed
US-6511974-B1 Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure WYETH 2003-01-28 US disclosed
CN-1391476-A Vasopressin agonist formulation and process AMERICAN CYANAMID CO (US) 2003-01-15 CN disclosed
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 EP disclosed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 WO disclosed
CN-1272111-A Tricyclic vasopressin agonists AMERICAN HOME PROD (US) 2000-11-01 CN disclosed
EP-1000062-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
WO-1999006409-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed
EP-0031796-B1 4-HETEROCYCLYL-4'-VINYL-STILBENES CIBA-GEIGY AG (CH) 1985-01-23 EP disclosed
US-4366189-A WHITENERS CIBA-GEIGY CORPORATION (US) 1982-12-28 US disclosed
EP-0031796-A2 4-Heterocyclyl-4'-vinyl-stilbenes CIBA-GEIGY AG (CH) 1981-07-08 EP disclosed